Compounding Chemotherapy Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 6.92 Bn

Forecast Year, 2035

USD 13.36 Bn

CAGR, 2026 - 2035

6.80%

Report Coverage

Global

What is the Compounding Chemotherapy Market Size in 2026?

The global compounding chemotherapy market size was calculated at USD 6.92 billion in 2025 and is predicted to increase from USD 7.39 billion in 2026 to approximately USD 13.36 billion by 2035, expanding at a CAGR of 6.80% from 2026 to 2035. The compounding chemotherapy market is expected to grow rapidly due to the increasing prevalence of cancer patients, higher demand for personalized dosage forms tailored to a patient's medical history, and the adoption of robotic and sterile compounding technologies for achieving effective results.

Key Takeaways

• North America led the global compounding chemotherapy market with 38.40% market share in 2025.
• The Asia Pacific is observed to be the fastest-growing region in the foreseeable period.
• By offering, the outsourced sterile compounding services segment held a dominant position in the market with a share of 34.60% in 2025.
• By offering, the closed system transfer devices segment is expected to grow at the fastest CAGR of 8.20% in the foreseen period.
• By preparation format, the patient-specific doses segment accounted for a considerable revenue share of 41.50% share in 2025.
• By preparation format, the ready-to-administer syringes segment is expected to grow with the highest CAGR of 9.10% in the forecast period.
• By care setting, the hospital pharmacies segment registered its dominance over the global compounding chemotherapy market with a share of 49.60% in 2025.
• By care setting, the home infusion pharmacies segment is expected to expand rapidly in the market with a CAGR of 8.10% in the forecast period.
• By compounding technology, the biological safety cabinets segment dominated the global market with a share of 22.60% in 2025.
• By compounding technology, the robotic compounding systems segment is expected to witness the fastest growth with the highest CAGR of 10.80% in the foreseen period.

What is the Compounding Chemotherapy Market?

The compounding chemotherapy market covers sterile preparation solutions and services used to produce patient-specific or standardized antineoplastic doses in controlled pharmacy environments. It includes in-house workflows and outsourced sterile compounding, supported by cleanroom equipment, isolators, robotic compounding, gravimetric verification, and closed system transfer devices to reduce exposure risk and improve accuracy. The market value includes service fees, equipment sales, software , consumables, and validation support used by hospitals, oncology centers, and infusion providers for safe, timely chemotherapy administration.

Role of Technology in the Growth of Compounding Chemotherapy Market

• Use of Automated Devices: Use of gravimetric and volumetric automated devices for high-precision, real-time, or volume measurement for accurate dosage helps fuel the growth of the market.
• Advanced Technology: Use of AI and analytics for stability prediction, dose calculation, and optimizing inventory management is also a major market driver.
• Pharmacy Technicians: Such technicians specialize in operating, calibrating, and troubleshooting advanced robotic equipment.

Compounding Chemotherapy Market Trends

• Personalized Medications: Higher demand for personalized medications, with the help of technological advancements and robotic arms for precise dosing, helps in the surge of the market.
• Strict Regulatory Standards: Compliance with enhanced safety standards for sterile and hazardous drug preparation also elevates the market's growth.
• Automated Compounding: Robotic arms are helpful for sterile compounding. It helps to lower human error and also lowers the probability of any risk, human contact, or contamination.

Market Scope

Segmental Insights

Offering Insights

Which Component of the Offering Segment led the global Market in 2025?

The outsourced sterile compounding services segment led the global compounding chemotherapy market with 34.60% share in 2025. The segment's growth is majorly driven by factors such as growing demand for high-quality, USP compliant, patient-specific sterile formulations. The segment also helps to eliminate the risks of contamination and lower the burden of managing skilled personnel shortages. The segment is also helpful for patient-specific treatment options for effective and quicker results. Such facilities are also crucial in a few nations for providing sterile, ready-to-administer chemotherapy and are helpful for hospitals and clinics to manage operational costs.

The closed system transfer devices segment is observed to be the fastest growing segment in the foreseen period with 8.20% CAGR. The segment's growth is mainly fueled by higher demand for worker and patient safety requirements. Rising oncology cases, strict regulatory guidelines, and preventing hazardous drug exposure during the drug formulation also propel the market's growth. Syringe safety devices, bag access devices, and vial access devices are the dominant factors of the segment, helpful for the segment's growth in the foreseen period. Luer-lock systems, helpful to keep the formulations intact from any adulteration, along with maintaining worker and patient safety, are also an essential market driver.

Preparation Format Insights

Why did the Patient-Specific Doses Segment lead the Global Market in 2025?

The patient-specific doses segment had a major dominance over the compounding chemotherapy market with 41.50% share in 2025. The segment involves personalization of anticancer drugs as per a patient's requirements rather than following the ‘one-size-fits-all' methodology. The procedure involves mixing precise amounts of medication based on a patient's metrics for effective and quicker results. The segment also focuses on factors such as customizing medication strength and concentration for a patient's tailored care. Personalized formulations are also helpful to lower the side effects of such drugs.

The ready-to-administer syringes segment is observed to have the highest CAGR of 9.10% in the forecast period. The segment's growth is mainly driven by factors such as enhanced safety, effective results, and the improved oncology sector. Such syringes can be customized as per a patient's medical requirements, aiding in a patient's effective and speedy recovery. Such syringes are also essential to lower the risk of contamination and minimize medication errors. They also allow for the rapid administration of hazardous drugs.

Care Setting Insights

Which Component of the Care Setting Segment Leads the Global Market in 2025?

The hospital pharmacies segment had a major dominance over the compounding chemotherapy market with 49.60% share in 2025. The segment's growth is mainly driven by the availability of trained personnel in such pharmacies, expertise in managing situations like drug shortages, and advanced sterile compounding capabilities. Hospital pharmacies also aid in managing the drug strengths and forms to meet a patient's needs. The segment is also driven by increasing cancer prevalence, the requirement of customized dosages, and the adoption of technologically advanced devices, such as robotics, to fuel the industry's growth.

The home infusion pharmacies segment is expected to grow at the fastest CAGR of 8.10% in the forecast period. The segment involves the preparation of customized chemotherapy medications directly in a patient's home to enable effective treatment outside the hospital. Such pharmacies also ensure sterile, accurate, and safe dosage options to treat a patient with the ease of staying at home. Such pharmacies are highly essential for elderly patients who cannot visit hospitals regularly for treatment. Home-based services got a major push in all domains since COVID.

Compounding Technology Insights

Why did the Biological Safety Cabinets Dominate Market in 2025?

The biological safety cabinets segment registered major dominance over the compounding chemotherapy market with 22.60% share in 2025. It is a specialized, ventilated, and HEPA-filtered primary engineering control to prepare hazardous and sterile drugs. The segment's growth is also fueled by its higher demand in compounding pharmacies, oncology departments, and pharmaceutical manufacturing . Smart cabinets with IoT connectivity, real-time air pressure monitoring, and low-pressure HEPA systems also propel the industry's growth.

The robotic compounding systems segment is observed to expand rapidly with 10.80% CAGR in the forecast period. The segment's main aim involves precision, reduced contamination risks, and improved efficiency. The preparation of hazardous drugs is also automated with the help of such drugs. Growing demand for personalized medications to treat cancer is one of the major requirements fueling the market's growth in the foreseeable period. The segment also focuses on efficiently managing the workforce shortage in pharmacies. The segment also provides long-term economic benefits to manage labor, waste reduction, and enhance safety.

Regional Insights

North America Compounding Chemotherapy Market Size and Growth 2026 to 2035

The North America compounding chemotherapy market size is estimated at USD 2.66 billion in 2025 and is projected to reach approximately USD 5.20 billion by 2035, with a 6.93% CAGR from 2026 to 2035.

Why did North America lead the global Compounding Chemotherapy Market in 2025?

North America led the global market with 38.40% share in 2025. The market in the region is observed to grow significantly due to growing cases of cancer, advanced healthcare infrastructure, and growing demand for personalized medications to cure the hazardous disease. The market also observes growth due to growing focus on robotic and sterile compounding. Higher demand for automation for precision and ensured sterility also helps to fuel the market's growth. Strict adherence to safety protocols for sterile compounding also fuels the growth of the industry.

U.S. Compounding Chemotherapy Market Size and Growth 2026 to 2035

The U.S. compounding chemotherapy market size is calculated at USD 1.99 billion in 2025 and is expected to reach nearly USD 3.92 billion in 2035, accelerating at a strong CAGR of 7.01% between 2026 and 2035.

The U.S. Compounding Chemotherapy Market Trends

The U.S. has a major contribution to the growth of the market due to the growing prevalence of cancer patients, leading to higher demand for technologically advanced treatment options for quicker and more effective results. Automation helps the market for enhanced precision and manages worker shortages as well.

Why is the Asia Pacific Observed to be the Fastest Growing Region in the Foreseen Period?

Asia Pacific is observed to expand rapidly with the highest CAGR in the forecast period. The market majorly observes growth due to higher demand for personalized medications to treat the growing cases of cancer in people of different age groups. Improving healthcare infrastructure and automation also make a major contribution to the market's growth. Major shift towards personalized and dose-specific treatment options also propels the industry's growth. The market also observes growth due to higher demand for cost-effective options in the region.

China Compounding Chemotherapy Market Trends

China has made a major contribution to the market's growth in the foreseeable period due to the major investment of the country in the automation of hospital pharmacy. Growing demand for targeted therapies, improved regulatory standards, and sterile compounding in hospitals also help to elevate the market's growth. Major shift of the industry in the region towards the use of robotic arms for improved precision and safety also fuels the market's growth in the foreseen period.

Compounding Chemotherapy Market Value Chain Analysis

Compounding Chemotherapy Market Companies

• Baxter International Inc .
• B. Braun Melsungen AG
• Fresenius Kabi AG
• Grifols, S.A.
• ICU Medical, Inc.
• PharMEDium (Cencora, formerly AmerisourceBergen)
• Nephron Pharmaceuticals Corporation
• QuVa Pharma, Inc.
• Wells Pharma of Houston, LLC
• Fagron NV
• Wedgewood Pharmacy
• McKesson Corporation (Oncology & Specialty)
• CAPS (Central Admixture Pharmacy Services)
• Cantrell Drug Company
• Empower Pharmacy

Segments Covered in the Report

By Offering

• Outsourced sterile compounding services
• In-house compounding systems
• Closed system transfer devices
• Sterile compounding consumables
• Validation and compliance services

By Preparation Format

• Patient-specific doses
• Batch-compounded doses
• Ready-to-administer syringes
• Ready-to-administer IV bags
• Clinical trial preparations

By Care Setting

• Hospital pharmacies
• Oncology clinics
• Ambulatory infusion centers
• Home infusion pharmacies
• Academic medical centers

By Compounding Technology

• Biological safety cabinets
• Compounding aseptic isolators
• Robotic compounding systems
• Gravimetric verification systems
• Environmental monitoring systems
• Label verification systems

By Region

• North America
• Latin America
• Europe
• Asia-pacific
• Middle and East Africa